

BOLOGNA, W. et al  
Serial No. unknown

**REMARKS**

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page(s) is captioned "Version With Markings To Show Changes Made."

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: 

Arthur R. Crawford  
Reg. No. 25,327

ARC:ecb  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE SPECIFICATION**

Page 1, before the first line, insert as a separate paragraph:

This application is the US national phase of international application  
PCT/EP00/09708 filed 4 October 2000, which designated the US.

**IN THE CLAIMS**

11. The composition of ~~either of claims 5 or 9~~ wherein the agonist is used to  
treat endometriosis.

12. The composition of ~~either of claims 5 or 9~~ wherein the agonist is used to  
treat infertility or to improve fertility.

20. The method of ~~either of claims 15 or 19~~, wherein the composition is  
administrated every 12 to 96 hours.

21. The method of ~~either of claims 15 or 19~~, wherein composition is  
administrated twice weekly.

22. Te method of ~~either of claims 15 or 19~~, wherein the composition further  
comprises a tablet.

BOLOGNA, W. et al  
Serial No. unknown

25. Use accordingly to claim 23-~~or~~24 wherein the medicament is formulated to deliver from less than 1 mg to 8 mg of the  $\beta$ -adrenergic agonist per dose.

26. Use according to ~~any one of claim 23 to 25~~ wherein the  $\beta$ -adrenergic agonist is terbutaline.

27. Use according to ~~any one of claims 23 to 26~~ wherein the medicament is formulated to deliver from less than 1 mg to 8 mg of the  $\beta$ -adrenergic agonist per dose.

28. Use according to ~~any one of claims 23 to 27~~ wherein the bioadhesive carrier comprises a cross-linked water-insoluble but water-swellaable polycarboxylic acid polymer.

32. Use according to claim 30-~~or~~31 wherein the medicament is for administration every 12 to 96 hours.

33. Use according to claim 30-~~or~~31 wherein the medicament is for administration twice weekly.

34. Use according to ~~any one of claims 23 to 33~~ wherein the medicament avoids detrimental blood levels of the  $\beta$ -adrenergic agonist.

BOLOGNA, W. et al  
Serial No. unknown.

35. Use according to ~~any one of claims 23 to 34~~ wherein the medicament is  
presented in tablet form.